{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:59:08Z","timestamp":1784138348548,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ejphar.2023.175625","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T12:43:38Z","timestamp":1680007418000},"page":"175625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling"],"prefix":"10.1016","volume":"947","author":[{"given":"Ramakrishna","family":"Nirogi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Ramalingayya","family":"Grandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshbabu","family":"Medapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narender","family":"Ganuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renny","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagadeesh Babu","family":"Thentu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veera Raghava Chowdary","family":"Palacharla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Petlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheshwari","family":"Srirangavaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramkumar","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasa Rao","family":"Ravella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar Reddy","family":"Gagginapally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Benade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Jayarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rasheed","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2023.175625_bib1","article-title":"Aducanumab therapy to treat Alzheimer's disease: a narrative review","volume":"9343514","author":"Beshir","year":"2022","journal-title":"Int. J. Alzheimer's Dis."},{"key":"10.1016\/j.ejphar.2023.175625_bib2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0306-4522(96)00666-5","article-title":"Effects of serotonin through serotonin1A and serotonin4 receptors on inhibition in the Guinea-pig dentate gyrus in vitro","volume":"78","author":"Bijak","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2023.175625_bib3","first-page":"39","article-title":"5-HT4 receptors","volume":"3","author":"Bockaert","year":"2004","journal-title":"Curr. Drug Targets: CNS Neurol. Disord."},{"key":"10.1016\/j.ejphar.2023.175625_bib4","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.neuropharm.2008.05.013","article-title":"5-HT(4) receptors: history, molecular pharmacology and brain functions","volume":"55","author":"Bockaert","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2023.175625_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/(SICI)1098-2396(200004)36:1<35::AID-SYN4>3.0.CO;2-Y","article-title":"Mapping of serotonin 5-HT(4) receptor mRNA and ligand binding sites in the post-mortem human brain","volume":"36","author":"Bonaventure","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.ejphar.2023.175625_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","article-title":"Drug treatments in Alzheimer's disease","volume":"16","author":"Briggs","year":"2016","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejphar.2023.175625_bib7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/sj.bjp.0707178","article-title":"5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL\/6j mice","volume":"150","author":"Cachard-Chastel","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175625_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/00001756-199406020-00018","article-title":"5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex","volume":"5","author":"Consolo","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2023.175625_bib9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13195-021-00838-z","article-title":"Aducanumab produced a clinically meaningful benefit in association with amyloid lowering","volume":"13","author":"Cummings","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.ejphar.2023.175625_bib10","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00018-019-03404-x","article-title":"Deciphering the neuroprotective and neurogenic potential of soluble amyloid precursor protein alpha (sAPP\u03b1)","volume":"77","author":"Dar","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2023.175625_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neulet.2016.01.055","article-title":"Chronic 5-HT4 receptor agonist treatment restores learning and memory deficits in a neuroendocrine mouse model of anxiety\/depression","volume":"616","author":"Darcet","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2023.175625_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nprot.2006.2","article-title":"T-maze alternation in the rodent","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejphar.2023.175625_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0169-328X(94)90392-1","article-title":"Identification and characterization of serotonin 5-HT4 receptor binding sites in human brain: comparison with other mammalian species","volume":"21","author":"Domenech","year":"1994","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.ejphar.2023.175625_bib14","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0026-895X(25)10130-2","article-title":"A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system","volume":"34","author":"Dumuis","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2023.175625_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0165-6147(00)89081-1","article-title":"Central 5-HT4 receptors","volume":"16","author":"Eglen","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2023.175625_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2023.175625_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/313577a0","article-title":"Functional innervation of cultured hippocampal neurones by cholinergic afferents from co-cultured septal explants","volume":"313","author":"Gahwiler","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2023.175625_bib18","series-title":"World Alzheimer's Report 2021: Journey through the Diagnosis of Dementia, Alzheimer's Disease International (ADI)","author":"Gauthier","year":"2021"},{"key":"10.1016\/j.ejphar.2023.175625_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.10505","article-title":"Parvalbumin, calbindin, or calretinin in cortically projecting and GABAergic, cholinergic, or glutamatergic basal forebrain neurons of the rat","volume":"458","author":"Gritti","year":"2003","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.ejphar.2023.175625_bib20","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/jnr.23823","article-title":"Restoring soluble amyloid precursor protein \u03b1 functions as a potential treatment for Alzheimer's disease","volume":"95","author":"Habib","year":"2017","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2023.175625_bib21","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.112.192351","article-title":"The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal \u03b8 oscillations","volume":"341","author":"Johnson","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.175625_bib22","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0301-0082(97)00028-2","article-title":"The cholinergic system in Alzheimer's disease","volume":"52","author":"Kasa","year":"1997","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejphar.2023.175625_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.neubiorev.2005.06.005","article-title":"Neural circuits and mechanisms involved in Pavlovian fear conditioning: a critical review","volume":"30","author":"Kim","year":"2006","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejphar.2023.175625_bib24","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/alz.12213","article-title":"Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019","volume":"17","author":"Knopman","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ejphar.2023.175625_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0531-5565(02)00157-2","article-title":"The serotonin 5-HT4 receptor and the amyloid precursor protein processing","volume":"38","author":"Lezoualc\u2019h","year":"2003","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.ejphar.2023.175625_bib26","series-title":"The Serotonin Receptors, from Molecular Pharmacology to Human Therapeutics","article-title":"5-HT3 and 5-HT4 receptors as targets for drug discovery for dementia authors: Frank Lezoualc'h and Magali Berthouze","author":"Lezoualc\u2019h","year":"2006"},{"key":"10.1016\/j.ejphar.2023.175625_bib27","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/ncb1007","article-title":"Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha","volume":"5","author":"Maillet","year":"2003","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejphar.2023.175625_bib28","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/1567205043332252","article-title":"New insights into serotonin 5-HT4 receptors : a novel therapeutic target for Alzheimer's disease?","volume":"1","author":"Maillet","year":"2004","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ejphar.2023.175625_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0306-4522(01)00302-5","article-title":"Evidence for glutamate, in addition to acetylcholine and GABA, neurotransmitter synthesis in basal forebrain neurons projecting to the entorhinal cortex","volume":"107","author":"Manns","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2023.175625_bib30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-3565(24)38802-0","article-title":"Evidence for involvement of central 5-HT4 receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies","volume":"296","author":"Matsumoto","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.175625_bib31","series-title":"International Conference on Alzheimer's Disease HT-01-07","article-title":"Results of a Phase 2A study of a novel 5HT4 agonist for the treatment of Alzheimer's Disease","author":"Megerian","year":"2008"},{"key":"10.1016\/j.ejphar.2023.175625_bib32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neuropharm.2007.06.016","article-title":"VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux","volume":"53","author":"Mohler","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2023.175625_bib33","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/jpet.102.034249","article-title":"SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties","volume":"302","author":"Moser","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2023.175625_bib34","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.2456612","article-title":"The coupling of neurotransmitter receptors to ion channels in the brain","volume":"241","author":"Nicoll","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2023.175625_bib35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/bmc.1347","article-title":"Quantification of acetylcholine, an essential neurotransmitter, in brain microdialysis samples by liquid chromatography mass spectrometry","volume":"24","author":"Nirogi","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.ejphar.2023.175625_bib36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s13318-012-0081-1","article-title":"Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats","volume":"37","author":"Nirogi","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejphar.2023.175625_bib37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejmech.2015.08.051","article-title":"Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease","volume":"103","author":"Nirogi","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175625_bib38","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/acs.jmedchem.8b00457","article-title":"Synthesis, structure-activity relationships, and preclinical evaluation of heteroaromatic amides and 1,3,4-oxadiazole derivatives as 5-HT4 receptor partial agonists","volume":"61","author":"Nirogi","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175625_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40261-021-01027-4","article-title":"First-in-Human studies to evaluate the safety, tolerability, and pharmacokinetics of a novel 5-HT4 partial agonist, SUVN-D4010, in healthy adult and elderly subjects","volume":"41","author":"Nirogi","year":"2021","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejphar.2023.175625_bib40","doi-asserted-by":"crossref","first-page":"10641","DOI":"10.1021\/acs.jmedchem.1c00703","article-title":"Discovery and preclinical characterization of usmarapride (SUVN-D4010): a potent, selective 5-HT4 receptor partial agonist for the treatment of cognitive deficits associated with Alzheimer's disease","volume":"64","author":"Nirogi","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2023.175625_bib41","series-title":"Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2004"},{"key":"10.1016\/j.ejphar.2023.175625_bib42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0031-9384(00)00434-0","article-title":"Social memory in the rat: circadian variation and effect of circadian rhythm disruption","volume":"72","author":"Reijmers","year":"2001","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2023.175625_bib43","doi-asserted-by":"crossref","first-page":"44881","DOI":"10.1074\/jbc.M109008200","article-title":"The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein","volume":"276","author":"Robert","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2023.175625_bib44","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1037\/0735-7044.107.5.887","article-title":"Contextual conditioning and auditory cue conditioning dissociate during development","volume":"107","author":"Rudy","year":"1993","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.ejphar.2023.175625_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1037\/0735-7044.108.2.227","article-title":"Ontogeny of contextual fear conditioning in rats: implications for consolidation, infantile amnesia, and hippocampal system function","volume":"108","author":"Rudy","year":"1994","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.ejphar.2023.175625_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2011.02.026","article-title":"5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: a pharmacodynamic and pharmacokinetic assessment","volume":"61","author":"Shen","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2023.175625_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1476-5381.1996.tb15154.x","article-title":"Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo","volume":"117","author":"Steward","year":"1996","journal-title":"Br. J. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992300136X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992300136X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:22:03Z","timestamp":1762143723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992300136X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":47,"alternative-id":["S001429992300136X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175625","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2023.175625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175625"}}